新聞與行事曆

Pfizer CEO Buys $1 Million of Stock Faizan Farooque Thu, August 13, 2026 at 10:20 PM GMT+10 1 min read PFE This article first appeared on GuruFocus . Pfizer Inc. ( PFE , Financials ) The pharmaceutical giant earned a new vote of confidence from its top executive . Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership interest to 429,172 shares.The reason people watch insider buying is that CEOs are already compensated very well based on how well the firm does, so buying shares on the open market is more inte…

(Image credit: Getty / Bloomberg) Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Email Share this article 4 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newsletter Elon Musk told employees of SpaceX that the power capacity of the company's xAI data centers will increase by 7x to 10GW by late 2027. If this happens, the company's data centers will bring the company some $300 billion – $500 billion in revenue per year, according to Musk. The claim comes as SpaceX's market capitalization dropped by nearly $570 billion in less th…

Image Credits: Microsoft AI Microsoft kills off unsuccessful AI features while merging its separate Copilot apps Sarah Perez 8:30 AM PDT · August 13, 2026 Two years ago, Microsoft described AI as a “generational shift” in technology that it wanted to lead. Today, the company is merging its Copilot-branded consumer and business apps, and ditching a number of unsuccessful AI features. As initially reported by GeekWire and detailed in Microsoft’s support documentation , the tech giant will combine the functionality of its consumer-facing Copilot app and the more business-oriente…

SUBSCRIBE Menu SUBSCRIBE Show Search Search Query Submit Search News Business Deals Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale August 13, 2026 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print iStock, Yutthana Gaetgeaw PTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several platforms. Amid the throes of bankruptcy, Sangamo Therapeutics has agreed to divest its Fabry disease program and a clutch of other assets and technolo…